| Richard Cordle, MD | |
|
4348 Electric Rd, Roanoke, VA 24018-0720 | |
| (540) 769-0976 | |
| (540) 857-5391 |
| Full Name | Richard Cordle |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Gastroenterology |
| Location | 4348 Electric Rd, Roanoke, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356313241 | NPI | - | NPPES |
| 010383722 | Medicaid | VA | |
| 1356313241 | Medicaid | VA | |
| 6702708 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0101-233252 (Virginia) | Secondary |
| 2080P0206X | Pediatrics - Pediatric Gastroenterology | 0101-233252 (Virginia) | Primary |
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.
According to 2021 research in the Orthopaedic Journal of Sports Medicine, 35 percent of athletes who have recovered from anterior cruciate ligament (ACL) injuries will re-injure it after returning to their sport.
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.
› Verified 6 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.
According to 2021 research in the Orthopaedic Journal of Sports Medicine, 35 percent of athletes who have recovered from anterior cruciate ligament (ACL) injuries will re-injure it after returning to their sport.
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.
› Verified 6 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.
According to 2021 research in the Orthopaedic Journal of Sports Medicine, 35 percent of athletes who have recovered from anterior cruciate ligament (ACL) injuries will re-injure it after returning to their sport.
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Cordle, MD 3027 Circle Dr Sw, Roanoke, VA 24018-2107 Ph: () - | Richard Cordle, MD 4348 Electric Rd, Roanoke, VA 24018-0720 Ph: (540) 769-0976 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.
According to 2021 research in the Orthopaedic Journal of Sports Medicine, 35 percent of athletes who have recovered from anterior cruciate ligament (ACL) injuries will re-injure it after returning to their sport.
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.
› Verified 6 days ago
Kevin Leal, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Camron L Johnson Privitera, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 21 Highland Ave Se, Ste 100, Roanoke, VA 24013 Phone: 540-344-9213 Fax: 540-345-7559 | |
Robert C Gard, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 21 Highland Ave Se, Ste 100, Roanoke, VA 24013 Phone: 540-344-9213 Fax: 540-345-7559 | |
Joseph Tamez, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 4348 Electric Rd, Roanoke, VA 24018 Phone: 540-769-0976 Fax: 540-857-5393 | |
Kaitlyn Bixel, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-224-4635 Fax: 540-985-9099 | |
Susan Smith, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 89 Summers Way, Roanoke, VA 24019 Phone: 540-992-1251 | |
Dr. Erinn E Hokanson, NP Pediatrics Medicare: Medicare Enrolled Practice Location: 4348 Electric Rd, Roanoke, VA 24018 Phone: 540-769-0975 Fax: 540-772-8219 |